Author: Li, Dongbo; Ji, Hongfei; Niu, Xingjian; Yin, Lei; Wang, Yiran; Gu, Yucui; Wang, Jinlu; Zhou, Xiaoping; Zhang, Han; Zhang, Qingyuan
Title: Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer Document date: 2019_12_19
ID: yj9mb88g_24
Snippet: Survival curves were analyzed using Kaplan-Meier method and curves were compared using the log-rank test. Multivariate survival analysis using the Cox regression proportional hazards model was carried out to adjust for clinical variables that may have statistical significance for prognosis in a univariate analysis. Results with P values <.05 were considered to be statistically significant (*P < .05, **P < .01). To examine the differences in the m.....
Document: Survival curves were analyzed using Kaplan-Meier method and curves were compared using the log-rank test. Multivariate survival analysis using the Cox regression proportional hazards model was carried out to adjust for clinical variables that may have statistical significance for prognosis in a univariate analysis. Results with P values <.05 were considered to be statistically significant (*P < .05, **P < .01). To examine the differences in the macrophages, cellular CD163 immunofluorescence and flow cytometry analysis were carried out on the MΦ, MS, and MR. CD163 is considered a polarization maker for TAM and M2. We found that CM from breast cancer cell lines increased CD163 expression in MΦ, indicating M2 polarization.
Search related documents:
Co phrase search for related documents- breast cancer cell line and cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- breast cancer cell line and flow cytometry: 1, 2
- breast cancer cell line and survival analysis: 1
- cancer cell line and cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- cancer cell line and flow cytometry: 1, 2, 3, 4, 5
- cancer cell line and survival analysis: 1, 2, 3, 4
- cell line and flow cytometry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- cell line and flow cytometry analysis: 1, 2, 3, 4
- cell line and log rank: 1, 2, 3
- cell line and log rank test: 1, 2, 3
- cell line and statistical significance: 1, 2, 3, 4
- cell line and survival analysis: 1, 2, 3, 4, 5, 6
- clinical variable and Cox regression: 1, 2, 3
- clinical variable and proportional hazard: 1
- clinical variable and proportional hazard model: 1
- clinical variable and statistical significance: 1, 2
- clinical variable and survival analysis: 1, 2
- clinical variable and univariate analysis: 1, 2
- Cox regression and flow cytometry: 1
Co phrase search for related documents, hyperlinks ordered by date